Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

MLA

Biagio Ricciuti, et al. “Use of Targeted next Generation Sequencing to Characterize Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibition in Small Cell Lung Cancer.” Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, Mar. 2019, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s40425-019-0572-6.

APA

Biagio Ricciuti, Sasha Kravets, Suzanne E. Dahlberg, Renato Umeton, Adem Albayrak, Safiya J. Subegdjo, Bruce E. Johnson, Mizuki Nishino, Lynette M. Sholl, & Mark M. Awad. (2019). Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. Journal for ImmunoTherapy of Cancer, 7(1), 1–9. https://doi.org/10.1186/s40425-019-0572-6

Chicago

Biagio Ricciuti, Sasha Kravets, Suzanne E. Dahlberg, Renato Umeton, Adem Albayrak, Safiya J. Subegdjo, Bruce E. Johnson, Mizuki Nishino, Lynette M. Sholl, and Mark M. Awad. 2019. “Use of Targeted next Generation Sequencing to Characterize Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibition in Small Cell Lung Cancer.” Journal for ImmunoTherapy of Cancer 7 (1): 1–9. doi:10.1186/s40425-019-0572-6.